Oncology Corporate Profile
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|SD-101 (+ anti PD-1)||toll-like receptor 9 (TLR9)||Melanoma||I|
|DV281||toll-like receptor 9 (TLR9)||Non Small Cell Lung Cancer (NSCLC)||I|
|SD-101 (+ anti PD-1)||toll-like receptor 9 (TLR9)||Squamous cell cancer of the head and neck (SCCHN)||I|
|SD-101 (+ anti IL-10)||toll-like receptor 9 (TLR9)||Various cancer types||I||Merck|
View additional information on product candidates here »